New targets and therapeutics for neuroprotection, remyelination and repair in multiple sclerosis.
Pablo VillosladaLawrence SteinmanPublished in: Expert opinion on investigational drugs (2020)
An enriched understanding of the neurobiology and molecular changes that are activated by inflammatory CNS damage will provide new opportunities for the identification of neuroprotective, remyelinating and regenerative therapies. Success will depend on the improvement of CNS drug delivery, the identification of new predictive biomarkers, the optimization of clinical trials by assessment of the damage to the visual pathway and the testing of novel therapies in acute optic neuritis.
Keyphrases
- multiple sclerosis
- drug delivery
- oxidative stress
- clinical trial
- blood brain barrier
- cerebral ischemia
- stem cells
- liver failure
- bioinformatics analysis
- mesenchymal stem cells
- respiratory failure
- small molecule
- cell therapy
- optical coherence tomography
- drug induced
- aortic dissection
- phase ii
- single molecule
- bone marrow
- phase iii
- open label
- extracorporeal membrane oxygenation
- double blind